Neuren highlights participation in PMSF Family Conference
Summary
Neuren was honoured to support and participate in the biannual Phelan-McDermid Syndrome Foundation Family Conference as the Presenting Sponsor.
Neuren CEO Jon Pilcher addressed the conference in both the opening and closing sessions and Chief Medical Officer Liza Squires presented Neuren’s development program for its investigative drug NNZ-2591, culminating in the ongoing Koala study - the first ever Phase 3 clinical trial for Phelan-McDermid syndrome.
Your question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.
Start the conversation
Ask Neuren Pharmaceuticals a question about this announcement.
Share your feedback
Discover